Shield TherapeuticsSTU:1JS EPS without NRI is €-0.02 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 786 Drug Manufacturers companies, Shield Therapeutics ranks better than 87.4% on this metric.
Shield Therapeutics's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was €-0.01.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 50.10% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 17.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Shield Therapeutics's EPS without NRI or its related term are showing as below:
STU:1JS'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -74.5 Med: 27.5 Max: 50.1
Current: 50.1
During the past 12 years, Shield Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 50.10% per year. The lowest was -74.50% per year. And the median was 27.50% per year.
STU:1JS's 3-Year EPS without NRI Growth Rate is ranked better than 87.4% of 786
companies
in the Drug Manufacturers industry
Industry Median: 9.7
vs STU:1JS: 50.10
Shield Therapeutics's EPS (Basic) for the
six
months ended in Dec. 2025 was €-0.01.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.02.
Shield Therapeutics (STU:1JS) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Shield Therapeutics EPS without NRI Related Terms
Shield Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Shield Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1JS vs ZTS, UTHR, VTRS: EPS without NRI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shield Therapeutics PE Ratio without NRI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Shield Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shield Therapeutics (STU:1JS) has a EPS without NRI of €-0.02 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Shield Therapeutics and its competitors. According to the industry distribution chart, Shield Therapeutics ranks #99 out of 786 companies in the Drug Manufacturers industry, placing it in the top 12.6%.
Is Shield Therapeutics' EPS without NRI too high?
Shield Therapeutics' current EPS without NRI is €-0.02. Based on the distribution chart, Shield Therapeutics ranks #99 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Shield Therapeutics' EPS without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shield Therapeutics ranks #99 out of 786 companies for EPS without NRI. This places Shield Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 9.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Drug Manufacturers company?
The median EPS without NRI among Drug Manufacturers companies is 9.70, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Shield Therapeutics and its competitors. For the Drug Manufacturers industry, the median EPS without NRI is 9.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shield Therapeutics's current EPS without NRI is €-0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current EPS without NRI is €-0.02. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current EPS without NRI is €-0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1JS has been successfully added to your 